Paul I. Terasaki

Nomenclature for factors of the HLA system, 2010

The WHO Nomenclature Committee for Factors of the HLA System met following the 14th International HLA and Immunogenetics Workshop in Melbourne, Australia in December 2005 and Buzios, Brazil during the 15th International HLA and Immunogenetics Workshop in September 2008. This report documents the additions and revisions to the nomenclature of HLA specificities following the principles established in previous reports (1–18).

Nomenclature for Factors of the HLA System, 1994

1. Several clones should have been sequenced. 2. Sequencing should have been performed in both directions. 3. An accession number in a databank should have been obtained. 4. Full length sequences are preferable though not essential. 5. Where possible a paper should have been submitted for publication. 6. DNA or other material, in particular cell lines, should be made available in a publicly accessible repository or at least in the originating laboratory. Documentation on this will be maintained by the Nomenclature Committee.

Nomenclature for factors of the HLA system, 2002

This chapter provides the nomenclature for factors of the HLA system, 2002. A number of previously described class I and II gene fragments within the HLA region are named in this system. Official designations are given to these gene fragments. The names LMP2 and LMP7 used previously for the two proteasome genes in the HLA class II region have been renamed by the Human Genome Nomenclature committee (HGNC) as PSMB9 and PSMB8, respectively. This system introduces the additional digit for synonymous variation and all allele names that are currently five digits or above are renamed accordingly. The use of an optional “N’” or “L” suffix to an allele name to indicate either “Null” or “Low” expression was introduced in previous Nomenclature Reports. Three new suffixes are introduced in this system. An “S” to denote an allele specifying a protein that is expressed as a soluble “Secreted” molecule but is not present on the cell surface; a “C” to indicate an allele product that is present in the “Cytoplasm” but not at the cell surface; an “A” to indicate “Aberrant” expression where there is some doubt as to whether a protein is expressed or not. There is evidence of differential splicing of HLA-G that leads to the production of both membrane-bound and soluble forms of the same allele. The IMGT/HLA Sequence Database contains sequences for all HLA alleles officially recognized by the WHO Nomenclature Committee for Factors of the HLA System and, provides users with online tools and facilities for their retrieval and analysis.

Nomenclature for factors of the HLA system, 2002.

This chapter provides the nomenclature for factors of the HLA system, 2002. A number of previously described class I and II gene fragments within the HLA region are named in this system. Official designations are given to these gene fragments. The names LMP2 and LMP7 used previously for the two proteasome genes in the HLA class II region have been renamed by the Human Genome Nomenclature committee (HGNC) as PSMB9 and PSMB8, respectively. This system introduces the additional digit for synonymous variation and all allele names that are currently five digits or above are renamed accordingly. The use of an optional “N’” or “L” suffix to an allele name to indicate either “Null” or “Low” expression was introduced in previous Nomenclature Reports. Three new suffixes are introduced in this system. An “S” to denote an allele specifying a protein that is expressed as a soluble “Secreted” molecule but is not present on the cell surface; a “C” to indicate an allele product that is present in the “Cytoplasm” but not at the cell surface; an “A” to indicate “Aberrant” expression where there is some doubt as to whether a protein is expressed or not. There is evidence of differential splicing of HLA-G that leads to the production of both membrane-bound and soluble forms of the same allele. The IMGT/HLA Sequence Database contains sequences for all HLA alleles officially recognized by the WHO Nomenclature Committee for Factors of the HLA System and, provides users with online tools and facilities for their retrieval and analysis.

An update to HLA Nomenclature, 2010

The WHO Nomenclature Committee for Factors of the HLA System met during the 15th International Histocompatibility and Immunogenetics Workshop in Buzios, Brazil in September 2008. This update is an extract of the main report that documents the additions and revisions to the nomenclature of human leukocyte antigen (HLA) specificities following the principles established in previous reports.

NOMENCLATURE FOR FACTORS OF THE HLA SYSTEM, 1990

This report contains complete lists of all the HLA class I and class 11 genes and sequences of alleles officially recognized. However, only references not previously cited are included. For a complete list of references this report should be read in conjunction with the 1989 report (Bodmer et al., 1990). For a complete list of all serologically defined specificities, which will not be updated until 1992, see the 1987 Nomenclature report (WHO Nomenclature Committee, 1988; Bodmer et al., 1989).

Nomenclature for Factors of the HLA System, 1995

The WHO Nomenclature Committee for factors of the HLA system met in Brighton in March 1995 at the joint meeting of the European Foundation for Immunogenetics and British Society for Histocompatibility and Immunogenetics to consider additions and revisions to the nomenclature of specificities defined by both molecular and serological techniques following the principles established in previous reports [l-121. sociated with the incorrect sequence is deleted. Names deleted on this basis are given in 2b. In some cases errors are suspected on the basis that they contain unexpected substitutions in normally conserved regions, but no material of the original sample is available for resequencing. As indicated in 2b, the names A*2401 and B*0701 have been deleted for this reason.